Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [3]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-42853 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- NT5DC2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Peptide sequence: IRKYDYNPSF AIRGLHYDIQ KSLLMKIDAF HYVQLGTAYR GLQPVPDEEV
- Concentration
- 0.5 mg/mL
Submitted references NT5DC2 promotes leiomyosarcoma tumour cell growth via stabilizing unpalmitoylated TEAD4 and generating a positive feedback loop.
Hu B, Zhou S, Hu X, Zhang H, Lan X, Li M, Wang Y, Hu Q
Journal of cellular and molecular medicine 2021 May 16;25(13):5976-87
Journal of cellular and molecular medicine 2021 May 16;25(13):5976-87
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human adult placenta cells using an anti-NT5DC2 polyclonal antibody (Product # PA5-42853).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human adult placenta cells using an anti-NT5DC2 polyclonal antibody (Product # PA5-42853).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human HT1080 cell lysate using an anti-NT5DC2 polyclonal antibody (Product # PA5-42853).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 3 NT5DC2 interacts with TEAD4 and reduces its ubiquitin-mediated degradation. A and B, Correlation analysis between the expression of NT5DC2 and TEAD4 in 80 LMS cases in TCGA (A) and in combined LMS cases and normal smooth muscle tissues (colon, small intestine and vagina) in GTEx (B). C, Comparison of TEAD4 expression in representative normal smooth muscle tissues, including colon (N = 308), small intestine (N = 92) and vagina (N = 85) from GTEx project and LMS tissues (N = 80). D, K-M survival analysis of PFS in 80 LMS cases in TCGA. Patients were separated into two groups according to the best cut-off of TEAD4 expression. E, Western blot analysis showing the relative TEAD4 expression in ST-LMS-1 and SK-UT-1 cells 48 h after infection of lentivirus carrying NT5DC2 shRNA or scrambled control. F, SK-LMS-1 and SK-UT-1 cells infected with NT5DC2 shRNA or scramble control were treated with MG132 (10 mumol/L, 6 h). The expression levels of TEAD4 and NT5DC2 were assessed by western blot assay. G, Co-IP assays were performed to check the interaction between endogenous NT5DC2 and TEAD4 in SK-LMS-1 (left) and SK-UT-1 (right) cells. IgG was used as a control. H, Cycloheximide pulse-chase assay was performed in SK-LMS-1 cells with mtTEAD4 overexpression alone or in combination with NT5DC2 knockdown or overexpression. 36 h after lentiviral infection, cells were treated with 10 mumol/L CHX for the indicated time, followed by western blot analysis. I, Co-localization of NT5DC2 (red
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 5 TEAD4 inhibition suppresses LMS cell proliferation in vitro and tumour growth in vivo. A and B, RT-qPCR analysis showing the relative TEAD4 expression in ST-LMS-1 (A) and SK-UT-1 (B) cells 48 h after infection of lentivirus carrying TEAD4 shRNA or scrambled control. C and D, Western blot assay of TEAD4 and NT5DC2 expression in ST-LMS-1 and SK-UT-1 cells 48 h after infection of lentivirus carrying TEAD4 shRNA or scrambled control. E and F, The proliferation of SK-LMS-1 (E) and ST-UT-1 (F) cells with or without TEAD4 knockdown. G, Representative images of colony formation (up) and quantitation or relative colony capability (down) of SK-LMS-1 (left) and SK-UT-1 (right) cells with or without TEAD4 knockdown. H and I, SK-LMS-1 cells infected with TEAD4 knockdown (shRNA) or scramble control were subcutaneously implanted into nude mice, and the tumours were harvested 4 weeks later (H). Compared with the controls, TEAD4 knockdown significantly inhibited tumour growth (I). *Comparison with sh NT5DC2 #1, # Comparison with sh NT5DC2 #2, * and # P